echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Br J Cancer: SBSN: a potential diagnostic and therapeutic target for bladder cancer

    Br J Cancer: SBSN: a potential diagnostic and therapeutic target for bladder cancer

    • Last Update: 2022-05-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Bladder cancer is the most common malignant tumor in the urinary system, accounting for 90%-95% of urothelial cancers


    Bladder cancer is the most common malignant tumor in the urinary system, accounting for 90%-95% of urothelial cancers


    Previous studies have shown that patients with non-muscle invasive bladder cancer have a higher survival rate, with a 5-year progression-free survival rate of 93% in the low-risk group and 54% even in the high-risk group





    SBSN (Suprabasin), a gene expressed in mouse and human differentiated keratinocytes, is a marker of epidermal differentiation and a potential precursor of the keratinized envelope




    SBSN enhanced the phosphorylation levels of EGFR and SRC kinases, which subsequently affected the phosphorylation and nuclear localization status of STAT3




    Zhou, Z.


    https://doi.
    org/10.
    1038/s41416-022-01794-7.


    Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.